EveryIntel

L2 Diagnostics, LLC

Publicly observed

New Haven, United States

Seen in a public record (e.g. a government grant database); not otherwise verified.

Details and provenance

ItemValueSourceStatus
CountryUSNIH RePORTER (opens in a new tab)
28 Sept 2026
Publicly observed
City / localityNew HavenNIH RePORTER (opens in a new tab)
28 Sept 2026
Publicly observed
NameL2 Diagnostics, LLCNIH RePORTER (opens in a new tab)
28 Sept 2026
Publicly observed
UEI (U.S. federal entity ID)GKA7VH5LFR25NIH RePORTER (opens in a new tab)
28 Sept 2026
Publicly observed

Recorded events

  1. Grant21 Sept 2026Publicly observed

    NIH SBIR/STTR award: A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (CLE)

    USD 323,090.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)

  2. Grant23 Sept 2025Publicly observed

    NIH SBIR/STTR award: A vaccine targeting mosquito metabolic pathways to eradicate malaria

    USD 300,065.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  3. Grant23 Sept 2025Publicly observed

    NIH SBIR/STTR award: A vaccine targeting mosquito metabolic pathways to eradicate malaria

    USD 299,644.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  4. Grant23 Sept 2025Publicly observed

    NIH SBIR/STTR award: A viral vector-based vaccine to induce humoral and cellular immune protection against Powassan virus in a tick transmission model

    USD 281,786.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  5. Grant21 Sept 2025Publicly observed

    NIH SBIR/STTR award: A Point of Care Test for Babesia microti

    USD 274,710.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  6. Grant21 Sept 2025Publicly observed

    NIH SBIR/STTR award: A Point of Care Test for Babesia microti

    USD 293,142.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  7. Grant15 Sept 2025Publicly observed

    NIH SBIR/STTR award: PfAg, a multivalent peptide vaccine against malaria

    USD 300,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  8. Grant15 Sept 2025Publicly observed

    NIH SBIR/STTR award: PfAg, a multivalent peptide vaccine against malaria

    USD 299,954.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  9. Grant17 Jul 2024Publicly observed

    NIH SBIR/STTR award: The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya

    USD 299,969.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  10. Grant8 Jul 2024Publicly observed

    NIH SBIR/STTR award: A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor

    USD 299,933.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  11. Grant1 Jun 2024Publicly observed

    NIH SBIR/STTR award: Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches

    USD 299,862.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

  12. Grant1 May 2024Publicly observed

    NIH SBIR/STTR award: A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens

    USD 299,250.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)

Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.